-
Featured Authors
-
Archives
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Monthly Archives: December 2012
Small Companies, Big Returns
The broader biotech indices are up more than 30 percent this year and have reached levels not seen since the peak of March 2000. Larger biotechs account for much of the index returns, as we have described previously, and have helped the sector outperform the S&P 500 by two fold. But how have smaller biotech companies been performing? As of Nov 30, 27 companies that started the year under $1 billion in market capitalization have Read More >
Are Politics Killing the U.S. Animal Biotech Industry?
A number of national newspapers ran an in-depth Associated Press article this week on the continuing saga of the AquAdvantage salmon and the challenge of its developer, Massachusetts-based AquaBounty Technologies, to stay afloat. The fish, genetically engineered to reach market weight in half the time of a conventional salmon, is a sustainable answer to the world’s demand for high-quality seafood protein, but its application for approval with the U.S. Food and Drug Administration (FDA) remains Read More >
BIO Housing Inventory Going Fast
With roughly 80,000 bioscience jobs in more than 3,500 businesses across all bioscience sectors, it is no wonder the 2013 BIO International Convention is returning to Chicago, April 22- 25, 2013. With a large presence in all biotech sectors – agricultural feedstock and chemicals, drugs and pharma, medical devices and equipment, research, testing and medical laboratories and bioscience-related distribution, attendees will have the opportunity to meet with and visit premier R&D facilities, from national laboratories Read More >
Data Exclusivity Protects Innovators and Assures Investors
Biotechnology companies must have some certainty that they can protect their investment in the development of new breakthrough therapies for a substantial period of time. This protection helps companies secure much-needed venture capital funding, which is the lifeblood of the industry. A failure to include substantial data exclusivity would undermine incentives to invest in biomedical innovation and thus would slow progress in the development of breakthrough therapies to improve the health and lives of patients Read More >
Tips for Building Your Brand at the 2013 BIO International Convention
Anxious to get a head start on your Convention planning but don’t know where to begin? Join the BIO Convention team’s monthly webinar series. Open to all attendees, pavilion organizers, delegations and prospective attendees, the webinar gives direct access to the drivers of the event, BIO staff. Last week’s webinar, Branding at BIO, focused on what to expect for exhibitor booth partnering, cost and time saving tips when dealing with Chicago union labor and how to Read More >
